[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578315":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":36,"locations":45,"responsibleParty":67,"collaborators":23,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":72,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":23,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":48,"whyStopped":23,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Zhejiang University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HLA-mismatch related","EXPERIMENTAL","The myeloablative conditioning is used when the patient is below 50 and with an HCT-CI\\\u003C2. The reduced intensity conditioning is used when the patient is over 50 or with an HCT-CI≥2.",[13,14,15,16],"Drug: Busulfan (Busulfex)","Drug: Cyclophosphamide (CTX)","Drug: Fludarabine (Fludara)","Drug: Semustine (MeCCNU)",[18,24,28,32],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Busulfan (Busulfex)","For myeloablative conditioning: Busulfan (Bu，3.2 mg\u002Fkg\u002Fd IV -8d \\~-6d) For reduced intensity conditioning: (Bu，3.2 mg\u002Fkg\u002Fd IV -7d\\~-5d)",[9],null,{"type":19,"name":25,"description":26,"armGroupLabels":27,"otherNames":23},"Cyclophosphamide (CTX)","Cyclophosphamide is only used in myeloablative conditioning (Cy，1.8g\u002Fm2, -5d, -4d)",[9],{"type":19,"name":29,"description":30,"armGroupLabels":31,"otherNames":23},"Fludarabine (Fludara)","For myeloablative conditioning: Fludarabine (Flu，30 mg\u002Fm2\u002Fd IV -6d \\~ -2d) For reduced intensity conditioning: Fludarabine（Flu，30mg\u002Fm2 \u002Fd IV -10d\\~-5d）",[9],{"type":19,"name":33,"description":34,"armGroupLabels":35,"otherNames":23},"Semustine (MeCCNU)","For both myeloablative and reduced intensity conditioning: Semustine (MECCNU，250 mg\u002Fm2 orally-3d).",[9],[37,42],{"name":38,"role":39,"phone":40,"phoneExt":23,"email":41},"Yanmin Zhao, MD., PhD","CONTACT","+86 87236706","yanminzhao@zju.edu.cn",{"name":43,"role":39,"phone":23,"phoneExt":23,"email":44},"Yishan Ye, MD., PhD","yeyishan@zju.edu.cn",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":50,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"The First Affiliated Hospital, Zhejiang University School of Medicine","RECRUITING","Hangzhou","China","310003","CN",{"type":54,"coordinates":55},"Point",[56,57],120.16142,30.29365,{"lat":57,"lon":56},[60,62,65],{"name":38,"role":39,"phone":61,"phoneExt":23,"email":41},"+86 57187236706",{"name":63,"role":64,"phone":23,"phoneExt":23,"email":23},"He Huang","PRINCIPAL_INVESTIGATOR",{"name":38,"role":66,"phone":23,"phoneExt":23,"email":23},"SUB_INVESTIGATOR",{"type":68,"investigatorFullName":63,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"SPONSOR_INVESTIGATOR","Professor, Director of the Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine","100578315","phase-1-human-leukocyte-antigen-hla-mismatched-related-allogeneic-hematopoietic-stem-cell-transplantation-100578315",false,"NCT06809699","Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation","A Prospective Single-arm Trial on Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation","HIGHT","Inclusion Criteria:\n\n* Adult patients (18-60 years old) with hematological malignancies and indications for hematopoietic stem cell transplantation with no available related human leukocyte antigen (HLA) identical sibling donors;\n* No available donor with HLA high-resolution typing ≥ 9\u002F10 or those who have difficulty finding donors due to urgent medical conditions;\n* No suitable HLA matching haploidentical donor available;\n* There is a suitable donor with mismatched HLA typing;\n* The subjects or their legal representatives shall sign an informed consent form before the start of the clinical study.\n\nExclusion Criteria:\n\n* Patients with severe liver and kidney function (alanine aminotransferase\\>2.5 times the upper limit of normal, blood creatinine\\>1.5 times the upper limit of normal) and cardiopulmonary dysfunction (New York Heart Association (NYHA) III\u002FIV heart function, ejection fraction\\\u003C50%, severe obstructive or restrictive ventilation dysfunction);\n* Merge active infections;\n* Eastern Cooperative Oncology Group (ECOG) score ≥ 2 points;\n* Secondary tumors with merged activity;\n* Severe central nervous system or mental illness leading to the inability to autonomously choose to enter or exit clinical trials;\n* Combine other allo HSCT contraindications.","ALL","18 Years","60 Years",{"count":82,"type":83},29,"ESTIMATED","INTERVENTIONAL",[86],"PHASE1","This study is a single center, prospective, single arm exploratory clinical trial that includes patients with hematological malignancies who are indicated for allogeneic hematopoietic stem cell transplantation (allo HSCT) but lack suitable donors. This project plans to use human leukocyte antigen (HLA) mismatched donors. Ultimately, a HLA mismatched allo HSCT transplantation plan will be established to improve the disease prognosis of these patients and truly enter the era of \"everyone has a donor\".",[89],"Hematologic Diseases",[91,92,93],"Hematopoietic cell transplantation","HLA mismatch related","Hematologic diseases","2025-01-30",{"date":96,"type":97},"2025-02-05","ACTUAL",{"date":99,"type":97},"2022-08-04",{"date":101,"type":83},"2027-10-31",{"name":63,"class":6},1]